BioForm Medical Strengthens Its Board of Directors With Three Aesthetics Industry Veterans



  -- Chris Dennis, Former Global President of OrthoNeutrogena
  -- Jeff Nugent, Former CEO of Revlon
  -- Dennis Condon, President of BioForm Medical and Former
     President of Mentor's Aesthetics Division

SAN MATEO, Calif., March 30, 2009 (GLOBE NEWSWIRE) -- BioForm Medical, Inc. (Nasdaq:BFRM) today announced it has, over the course of its current fiscal year, strengthened its Board of Directors with the addition of three seasoned executives with significant aesthetics industry experience. Chris Dennis, former Global President of OrthoNeutrogena, joined the Board of Directors in December 2008. Jeff Nugent, former CEO of Revlon and former Worldwide President and CEO of Neutrogena, joined the Board of Directors in February 2009. In addition, Dennis Condon, currently BioForm Medical's President and Chief Business Officer, and formerly a member of BioForm Medical's Board of Directors, has rejoined the Board of Directors in March 2009.

In evaluating and proposing nominees for election to the Board, BioForm Medical's Nominating and Corporate Governance Committee has guided the Board of Directors' transition from a predominantly venture capital-led to one led by industry veterans. Pursuant to this initiative, Jeff Nugent has replaced Dr. Albert Cha, a Managing Partner at Vivo Ventures, an early BioForm Medical investor, and Chris Dennis has replaced Dr. Evan Melrose, a Managing Partner of PTV Sciences, also an early BioForm Medical investor.

Chris Dennis is currently serving as an independent consultant to medical technology companies and most recently served as the Senior Vice President of Commercial Operations for Angiotech Pharmaceuticals, Inc. Mr. Dennis brings to BioForm Medical significant dermatology, medical aesthetics, and pharmaceutical industry expertise. Mr. Dennis previously held a number of senior management positions within various subsidiaries at Johnson & Johnson for over 17 years in marketing, sales and general management. Prior to joining Angiotech, Mr. Dennis was Global President of OrthoNeutrogena, a Johnson & Johnson company, where he was responsible for overall strategy and business growth initiatives.

Since May 2007, Jeff Nugent has served as the President and CEO of Ventus Medical, a privately-held medical device company focused on the development of a treatment for obstructive sleep apnea. Mr. Nugent also serves on the boards of directors of two privately-held medical aesthetics companies and is the Chairman of the board of directors of TRIA Beauty. Mr. Nugent brings to BioForm Medical significant experience and expertise in the medical aesthetics and consumer aesthetics markets. Most notably, Mr. Nugent served as President and CEO of Revlon from 1999 to 2002. Mr. Nugent previously held a number of senior management positions within Johnson & Johnson for over 20 years in R&D, operations, marketing and finance. Mr. Nugent served as Worldwide President and CEO of Neutrogena from the time of its acquisition by Johnson & Johnson through the first five years of its considerable growth as a global leader in professionally-recommended skin care.

Since June 2007, Dennis Condon has been BioForm Medical's President and Chief Business Officer and previously served as a member of BioForm Medical's Board of Directors from January 2004 to June 2007. From March 2006 to June 2007, he was the CEO and President of Apsara Medical, a medical device company focused on the aesthetics market. From February 2005 to November 2005, Mr. Condon was the President and CEO of Reliant Technologies Inc., a provider of lasers for aesthetic applications. Prior to joining Reliant Technologies, Mr. Condon was CEO of The Plastic Surgery Company, a healthcare services company and was President of Mentor's aesthetics division.

"We are delighted that Mr. Dennis, Mr. Nugent, and Mr. Condon have joined our Board of Directors at this important point in the Company's development. BioForm Medical is working diligently to weather the macroeconomic downturn and to position the business for rapid growth and profitability in a recovery. We have the opportunity to be a leader in the medical aesthetics industry, and our new Board members' industry expertise will be invaluable as we develop our strategies to build the company in the coming years," said Steve Basta, CEO of BioForm Medical. "We thank Dr. Albert Cha and Dr. Evan Melrose for their years of dedicated service and guidance."

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California, developing products that enhance aesthetic procedures performed in dermatology and plastic surgery practices. BioForm Medical's lead product is RADIESSE(r) dermal filler, a long-lasting filler for use in facial aesthetics. BioForm Medical is developing several future aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts. For more information about BioForm Medical, please visit www.bioform.com.



            

Contact Data